Nature of Organization and Operations - Narrative (Details) - USD ($) $ in Thousands				3 Months Ended		36 Months Ended	37 Months Ended
	Apr. 16, 2025	Mar. 25, 2025	Dec. 20, 2024	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2025	Dec. 31, 2024	Dec. 19, 2024	Mar. 17, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Accumulated deficit				$ 259,638		$ 259,638	$ 259,638	$ 332,654
Net income (loss)				73,016	$ (18,289)
Cash, cash equivalents, and short-term investments				231,100		$ 231,100	$ 231,100
Payment for in-licensing				8,788	$ 13,593
Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations | Aadi Subsidiary
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Disposal group, including discontinued operation, ownership percentage in disposed business									100.00%
Proceeds from divestiture of businesses		$ 102,400		$ 102,400
Sales Agreement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Issuance of common stock (in shares)							0
Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Issuance of common stock (in shares)				21,592,000
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Payment for in-licensing			$ 6,000
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Payment for in-licensing	$ 38,000
Value fee percentage	6.00%
Cowen and Company LLC | Common Stock | Sales Agreement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Maximum aggregate offering prices										$ 75,000
Issuance of common stock (in shares)						0